MedPath

UNITED THERAPEUTICS CORPORATION

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:1
Completed:1

Trial Phases

1 Phases

Phase 3:2

Drug Approvals

20

FDA:6
CANADA:5
NMPA:4

Drug Approvals

Treprostinil Injection

Product Name
曲前列尼尔注射液
Approval Number
H20140305
Approval Date
May 3, 2014
NMPA

Treprostinil Injection

Product Name
曲前列尼尔注射液
Approval Number
H20140308
Approval Date
May 3, 2014
NMPA

Treprostinil Injection

Product Name
曲前列尼尔注射液
Approval Number
H20140307
Approval Date
May 3, 2014
NMPA

Treprostinil Injection

Product Name
曲前列尼尔注射液
Approval Number
H20140306
Approval Date
May 3, 2014
NMPA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (100.0%)
No trials found

News

Liquidia Secures $50 Million Funding Following YUTREPIA Commercial Launch and Legal Victory

Liquidia Corporation received $50 million from Healthcare Royalty following the first commercial sale of YUTREPIA and a favorable court ruling denying United Therapeutics' injunction request.

World's First Bioengineered External Liver Assist Device Treats Patient in Groundbreaking Clinical Trial

United Therapeutics and Intermountain Health successfully treated the world's first patient with miroliverELAP, a bioengineered external liver assist device, marking the first human clinical trial of a manufactured organ alternative.

United Therapeutics Completes Enrollment of Phase 3 Trial for Once-Daily Oral PAH Treatment Ralinepag

United Therapeutics has concluded enrollment of 728 participants in the phase 3 ADVANCE OUTCOMES study evaluating ralinepag, a potential first-in-class once-daily oral prostacyclin agonist for pulmonary arterial hypertension.

United Therapeutics Completes Enrollment in Phase 3 TETON 1 IPF Trial of Inhaled Treprostinil

United Therapeutics has fully enrolled its Phase 3 TETON 1 study, evaluating nebulized Tyvaso (treprostinil) for idiopathic pulmonary fibrosis (IPF).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.